NCT06245876招募中不适用
Lung EpiCheck Biomarkers Development Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Nucleix Ltd.
- 入组人数
- 6,000
- 试验地点
- 10
- 主要终点
- Performance
研究概览
简要总结
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
详细描述
This is a prospective, multi-center, observational nonsignificant risk study aimed to collect blood and clinical data from primary lung cancer and control subjects to characterize various biomarkers that will discriminate between lung cancer and control subjects.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Performance
时间窗: Day 1
Performance of the assay in terms of (1) Sensitivity (2) Specificity (3) NPV (negative predictive value) and (4) PPV (positive predictive value).
次要结局
未报告次要终点
研究者
研究点 (10)
Loading locations...
相似试验
进行中（未招募）
不适用
Determination and Validation of a Multi-analyte Assay for Lung Cancer ScreeningLung CancerNCT04968548Nucleix Ltd.5,000
Unknown
不适用
'Lung Health Check' Biomarker StudyCancerLung CancerNCT04957433Royal Marsden NHS Foundation Trust1,000
已完成
不适用
Biomarkers for Diagnosis of Lung CancerLung CancerLung NeoplasmNCT02050100SK Medical (Beijing) Co., Ltd.300
招募中
不适用
Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.Lung CancerNCT06016569The Institute of Molecular and Translational Medicine, Czech Republic3,200
招募中
3 期
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsLung CancerNCT05055908Hunan Province Tumor Hospital12,000